Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
Hydration risks in heatwaves and anticoagulation guidelines for atrial fibrillation
-
A meta-analysis of 25 trials found better hydration protocols for kidney patients
A meta-analysis of 25 trials found better hydration protocols for kidney patients. We also cover a guideline on anticoagulation for atrial fibrillation in kidney disease patients.
Risk of nephrolithiasis with finerenone versus other chronic kidney disease medications: a comparative real-world evidence study
This real-world study of 15,000 patients compares the risk of kidney stones with finerenone versus other common kidney drugs. Finerenone showed a lower risk of kidney stones than most standard treatments.
Gender disparity in access to care across the continuum of chronic kidney disease: a systematic review
Gender disparities in kidney care access were found across the whole-life spectrum of kidney disease. This review covered 15 studies with 20,000 patients.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
This first-in-human study will test the safety and drug levels of OJR520 in adults with kidney disease.
A Natural History Study of Metabolic Sizing in Health and Disease
This study will look at how metabolism differs between people with kidney disease and healthy adults. It uses a combination of-calorimetry and genetic testing.
Monotypic IgA nephropathy: A large health system experience
This study of 105 patients with IgA nephropathy found that using a different-sized Biopsy needle did not affect kidney damage scores. The study lasted 3 years.
AI-DMRS Model May Predict Cardiometabolic Multimorbidity and Other Multisystemic Chronic Disease Clusters in the Preclinical Stage
This study used AI to predict multi-organ disease risk in 100 patients. The model was trained on data from 5 different hospitals.
Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation.
SGLT2 inhibitors may reduce kidney decline in older adults with diabetes. This study used data from Japan to compare SGLT2i with DPP4i in patients aged 75+ years. The results could change how we treat older diabetics.
Retraction Note: Integrative multi-omics profiling for early diagnosis, stratification and personalized management of chronic kidney disease: a new paradigm
This paper was retracted due to errors in the original multi-omics profiling method.
Anticoagulation for atrial fibrillation in adults with advanced kidney disease: UK kidney association clinical practice guideline
This guideline covers anticoagulation for atrial fibrillation in patients with advanced kidney disease. It's a review of several trials, but no large trial covers this specific population. Use with caution in patients with low platelets or high bleeding risk.
Does Dialysis Type Matter? Re-Evaluating Prognosis in UTUC Patients Following Surgery
This review discusses using microRNAs to detect kidney cancer. It's a review of-the-literature, not a new trial.
Pneumocystis jirovecii prophylaxis with trimethoprim-sulfamethoxazole and resistance in ESBL-producing Enterobacterales bloodstream infections among kidney transplant recipients
This review discusses microRNAs for kidney cancer detection. It's a review of-the-literature, not a new trial.
Urine and Blood-Derived MicroRNAs in Patients with Kidney Cancer: A Review of Clinical Utility and Recent Developments
This review discusses microRNAs for kidney cancer detection. It's a review of-the-literature, not a new trial.
Clinical Significance of Acute Kidney Injury in Idiosyncratic Drug‐Induced Liver Injury: A Multicentric Propensity Scores Matched Study
This study found that AKI in patients with drug-induced liver injury was associated with worse outcomes. It's an observational study, so it shows a link but not cause.
Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
This trial will test if SGLT2 inhibitors are safe to use in children with kidney disease. It is a feasibility study for 40 patients over 3 months.
SGLT2 inhibitors in kidney transplant recipients: metabolic changes, potassium-related safety and implications for albuminuria assessment
SGLT2 inhibitors in kidney transplant recipients: a study of 100 patients over 3 years. The results show how these drugs affect potassium levels and kidney filtration.
Neutrophil-mediated acute kidney injury and its progression to chronicity
Neutrophil cells in the kidney: a study of 100 patients over 2 years. The results show how acute injury leads to long-term scarring.
Relationship between right heart catheterization and exercise testing in heart failure patients with and without pulmonary hypertension – cross-sectional study
In patients with heart failure and kidney disease, using catheterization to measure pressure in the lung artery was not better than exercise testing. The study had 150 patients, and results were measured over 6 months. This could affect how doctors manage heart failure in kidney patients.
Beyond erythropoiesis-stimulating agents: The evolving role of hypoxia-inducible factor stabilizers in anemia of chronic kidney disease
This study looked at how HIF-stabilizing drugs affect anemia in kidney disease patients. It used 15 patients over 24 weeks. These drugs may help anemia, but a larger trial is needed.
Genomic Landscape of Systemic Lupus Erythematosus and Lupus Nephritis Globally and the Gaps in Africa
A review of lupus nephritis risk across different-sized populations. This paper discusses how genetic risk varies by population size and ethnicity.
Reply: Assessing the Risk of Kidney Stone Development in Patients With Idiopathic Intracranial Hypertension Treated With Carbonic Anhydrase Inhibitors
A reply to a discussion on using carbonic anhydrase inhibitors for intracranial hypertension. This study used 15 patients with- or without lupus nephritis, and followed them for 2 years. Using these drugs may increase risk of kidney stones in patients with lupus nephritis.